Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Benitec Biopharma (BNTC) Cash & Equivalents (2019 - 2025)

Historic Cash & Equivalents for Benitec Biopharma (BNTC) over the last 7 years, with Q1 2025 value amounting to $103.6 million.

  • Benitec Biopharma's Cash & Equivalents changed N/A to $103.6 million in Q1 2025 from the same period last year, while for Mar 2025 it was $103.6 million, marking a year-over-year change of. This contributed to the annual value of $50.9 million for FY2024, which is 195353.25% up from last year.
  • According to the latest figures from Q1 2025, Benitec Biopharma's Cash & Equivalents is $103.6 million.
  • Over the past 5 years, Benitec Biopharma's Cash & Equivalents peaked at $103.6 million during Q1 2025, and registered a low of $2.5 million during Q2 2023.
  • Over the past 5 years, Benitec Biopharma's median Cash & Equivalents value was $16.1 million (recorded in 2021), while the average stood at $28.5 million.
  • As far as peak fluctuations go, Benitec Biopharma's Cash & Equivalents crashed by 7945.27% in 2022, and later surged by 195353.25% in 2024.
  • Benitec Biopharma's Cash & Equivalents (Quarter) stood at $12.3 million in 2021, then decreased by 14.53% to $10.5 million in 2022, then surged by 93.6% to $20.4 million in 2023, then skyrocketed by 283.74% to $78.3 million in 2024, then surged by 32.32% to $103.6 million in 2025.
  • Its Cash & Equivalents stands at $103.6 million for Q1 2025, versus $78.3 million for Q4 2024 and $67.8 million for Q3 2024.